Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Lower-Risk MDS with Ring Sideroblasts (MEDALIST)
NCT02631070Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2016
- Primary completion
- Jun 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Luspatercept with Placebo (2 arms). Primary endpoint: Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) >= 8 Weeks. Started Feb 2016; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02631070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631070.